Phase I/II study of MEDI-522, a humanized monoclonal antibody directed against the human alpha V beta 3 integrin, in patients with irinotecan-refractory advanced colorectal cancer

Trial Profile

Phase I/II study of MEDI-522, a humanized monoclonal antibody directed against the human alpha V beta 3 integrin, in patients with irinotecan-refractory advanced colorectal cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 Dec 2009

At a glance

  • Drugs Etaracizumab (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 22 Dec 2009 Actual end date (1 Nov 2004) added as reported by ClinicalTrials.gov. (NCT00027729)
    • 22 Dec 2009 Actual end date (1 Nov 2004) added as reported by ClinicalTrials.gov. (NCT00027729)
    • 22 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov. (NCT00027729)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top